We should expect Novo Nordisk and Lilly to increase competitive intensity in 2025, while more markets will see head-on competition between the two as better supply allows semaglutide and tirzepatide to be launched in more countries
Personalized Peptide Therapy The future likely holds more personalized approaches where combinations of peptides are tailored to individual metabolic and health profiles, optimizing outcomes while minimizing side effects
For 0.25mg, draw 7.5 units
Angiotensin-converting enzyme inhibitorassociated elevations in serum creatinine: is this a cause for concern
For topical treatments like lip lightening creams and specialized lip balms, prices can range from 500 to 2,000 per product
REIMAGINE 3 was a 40-week efficacy and safety phase 3 trial of CagriSema 2.4 mg/2.4 mg and 1 mg/1 mg once-weekly versus placebo in 274 adults with type 2 diabetes as add-on to once-daily basal insulin with or without metformin